FHTX vs IDYA
FHTX: Foghorn Therapeutics is a clinical-stage biotech developing precision medicines by targeting the chromatin regulatory system to correct abnormal gene expression in cancer and other diseases. IDYA: IDEAYA Biosciences is a clinical-stage precision medicine company focused on discovering and developing targeted synthetic lethality therapies for oncology.
Side-by-side fundamentals
| Metric | FHTX | IDYA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $1.99 | $36.06 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-08) | $118M | $3.5B | |
| Net margin FY2025, SEC XBRL | -240.3% | -52.0% | IDYA higher |
| Operating margin FY2025, SEC XBRL | -279.5% | -72.8% | IDYA higher |
| ROE FY2025, SEC XBRL | n/a | -11.1% | |
| ROA FY2025, SEC XBRL | -37.5% | -10.2% | IDYA higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-09-03 | +52.0% | +3118.1% | IDYA higher |
| Revenue CAGR (3y) SEC XBRL | +17.1% | +62.5% | IDYA higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.59 | 0.97 | |
| 1-year return as of 2026-10-08 close | -55.8% | +34.4% | IDYA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.